Format

Send to

Choose Destination
Clin Cancer Res. 2019 Sep 1;25(17):5315-5328. doi: 10.1158/1078-0432.CCR-18-3314. Epub 2019 Jun 10.

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer.

Author information

1
Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, United Kingdom.
2
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
3
South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
4
Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
5
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
6
Human Biomaterials Resource Centre, University of Birmingham, Birmingham, United Kingdom.
7
Department of Pathology, Federal University of Espírito Santo, Espírito Santo, Brazil.
8
Division of Cancer Sciences, University of Manchester, Christie Hospital, Manchester Academic Health Science Centre, Manchester, United Kingdom.
9
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom.
10
The University of Chicago Medicine, Chicago, Illinois.
11
Department of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas.
12
NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
13
Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, United Kingdom. h.mehanna@bham.ac.uk.

Abstract

PURPOSE:

Intratumoral hypoxia and immunity have been correlated with patient outcome in various tumor settings. However, these factors are not currently considered for treatment selection in head and neck cancer (HNC) due to lack of validated biomarkers. Here we sought to develop a hypoxia-immune classifier with potential application in patient prognostication and prediction of response to targeted therapy.

EXPERIMENTAL DESIGN:

A 54-gene hypoxia-immune signature was constructed on the basis of literature review. Gene expression was analyzed in silico using the The Cancer Genome Atlas (TCGA) HNC dataset (n = 275) and validated using two independent cohorts (n = 130 and 123). IHC was used to investigate the utility of a simplified protein signature. The spatial distribution of hypoxia and immune markers was examined using multiplex immunofluorescence staining.

RESULTS:

Unsupervised hierarchical clustering of TCGA dataset (development cohort) identified three patient subgroups with distinct hypoxia-immune phenotypes and survival profiles: hypoxialow/immunehigh, hypoxiahigh/immunelow, and mixed, with 5-year overall survival (OS) rates of 71%, 51%, and 49%, respectively (P = 0.0015). The prognostic relevance of the hypoxia-immune gene signature was replicated in two independent validation cohorts. Only PD-L1 and intratumoral CD3 protein expression were associated with improved OS on multivariate analysis. Hypoxialow/immunehigh and hypoxiahigh/immunelow tumors were overrepresented in "inflamed" and "immune-desert" microenvironmental profiles, respectively. Multiplex staining demonstrated an inverse correlation between CA-IX expression and prevalence of intratumoral CD3+ T cells (r = -0.5464; P = 0.0377), further corroborating the transcription-based classification.

CONCLUSIONS:

We developed and validated a hypoxia-immune prognostic transcriptional classifier, which may have clinical application to guide the use of hypoxia modification and targeted immunotherapies for the treatment of HNC.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center